Clinical Trials Browser

INDUSTRY × enzalutamide × Breast × Clear all

NCT04557449 2025-10-01

CDK4i

Phase 2 Active not recruiting

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT02007512 2025-09-02

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Phase 2 Completed

247 enrolled 27 charts

Breast Neoplasms

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02091960 2025-04-04

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Phase 2 Completed

103 enrolled 17 charts

Breast Neoplasms

NCT01889238 2024-12-13

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

Phase 2 Completed

118 enrolled 23 charts

Breast Neoplasms

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

49 enrolled 33 charts

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT01597193 2019-05-08

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Phase 1 Completed

101 enrolled 33 charts

Breast Neoplasms

NCT02929576 2018-10-22

ENDEAR

Phase 3 Withdrawn

Breast Neoplasms, Neoplasm Metastasis